Insmed (NASDAQ:INSM) Now Covered by Analysts at Jefferies Financial Group

Investment analysts at Jefferies Financial Group initiated coverage on shares of Insmed (NASDAQ:INSM - Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set a "buy" rating and a $105.00 price target on the biopharmaceutical company's stock. Jefferies Financial Group's price target suggests a potential upside of 56.20% from the company's current price.

INSM has been the topic of a number of other research reports. Wells Fargo & Company lifted their target price on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research report on Wednesday, February 19th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Insmed in a report on Wednesday, March 19th. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Insmed in a report on Monday. JPMorgan Chase & Co. increased their target price on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, Insmed currently has an average rating of "Moderate Buy" and a consensus target price of $94.63.

Insmed Trading Up 2.5%

INSM traded up $1.61 during midday trading on Tuesday, reaching $67.22. 1,283,588 shares of the company were exchanged, compared to its average volume of 2,327,732. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed has a one year low of $21.92 and a one year high of $84.91. The stock has a market capitalization of $12.22 billion, a P/E ratio of -12.03 and a beta of 0.84. The stock's 50-day simple moving average is $71.68 and its 200 day simple moving average is $73.12.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The business had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. During the same quarter last year, the firm earned ($1.06) EPS. The company's revenue for the quarter was up 22.9% on a year-over-year basis. As a group, analysts forecast that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 18,750 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares of the company's stock, valued at $27,079,091.58. This trade represents a 5.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Sara Bonstein sold 18,322 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total value of $1,471,439.82. Following the sale, the chief financial officer now directly owns 118,863 shares of the company's stock, valued at $9,545,887.53. This represents a 13.36% decrease in their position. The disclosure for this sale can be found here. Insiders sold 150,559 shares of company stock worth $11,056,634 over the last ninety days. 3.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Insmed

A number of hedge funds have recently added to or reduced their stakes in INSM. Cullen Frost Bankers Inc. boosted its position in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 221 shares during the last quarter. Elequin Capital LP purchased a new position in shares of Insmed in the fourth quarter valued at $28,000. Steward Partners Investment Advisory LLC lifted its holdings in Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares in the last quarter. NBC Securities Inc. purchased a new stake in Insmed during the 1st quarter worth about $49,000. Finally, V Square Quantitative Management LLC lifted its holdings in Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 248 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.